Launch of India's First Indigenous IBR Vaccine

The Indian Immunologicals (IIL) has introduced India's first indigenously developed vaccine against infectious bovine rhinotracheitis (IBR), known as Raksha-IBR. This development marks a significant step in addressing the disease's impact on infertility, abortions, and decreased milk productivity in cattle.

Key Points

• Event Information:
  • The vaccine launch coincided with the diamond jubilee celebration of the National Dairy Development Board (NDDB) in Anand, Gujarat, on September 27.
  • Prominent attendees included Narendra Pal Gangwar, Secretary to the Centre’s Department of Animal Husbandry and Dairying; Meenesh C. Shah, NDDB Chairman; and K. Anand Kumar, IIL MD.
• About IBR:
  • IBR is endemic in India and caused by the Bovine Herpes Virus (BHV-1).
  • The disease is transmitted through the aerosol route and affects the reproductive systems of cattle.
  • It is also spread by semen from infected bulls to milch animals.
  • Major impacts include infertility, abortions, and reduced milk productivity.
• Vaccine Details:
  • The vaccine, Raksha-IBR, is a glycoprotein E (gE) deleted DIVA marker vaccine.
  • Marker vaccines help differentiate between infected and vaccinated animals.
  • There was no previous vaccine or specific treatment for IBR in India.
• Importance of the Vaccine:
  • Systematic vaccination and biosecurity are crucial to prevent IBR.
  • Enhancing productivity in India's dairy sector is vital as India is the largest milk producer globally.
  • The use of quality semen from bulls with superior genetics is essential for improving productivity.
  • Efforts to develop superior genetic bulls are undermined if animals contract the IBR virus.